Nothing new but I like the way he puts it phrases like impressive experienced managment team
Unilife Medical Solutions (UNIFF.PK) is in the process of obtaining a primary U.S. listing on the NASDAQ as part of its relocation to Central Pennsylvania where the company began manufacturing the FDA-cleared Unitract 1mL Insulin Syringe in August 2009. Unilife boasts an impressive, experienced management team that delivers on its objectives – as evidenced by the company’s Industrialization Program for the Unilife Ready-to-Fill Syringe that is one year ahead of schedule, targeting completion by the end of 2010.
Click here for my previous article coverage of Unilife at BioMedReports.com, beginning in late March when the stock was trading around the 25 cent range with little to no volume for the U.S. Pink Sheet listing (UNIFF.PK) which is quickly approaching $1/share as the company nears a NASDAQ listing. In addition, the research section of BioMedReports.com includes a report by Griffin Securities with a US$3 price target and the company’s most recent corporate presentation. Highlights from the report include the following:
1. Unilife has a disruptive drug delivery technology with a sound strategy to enter the U.S. and European needle and syringe markets
2. Unilife has a big pharma partner in Sanofi-Aventis (NYSE:SNY), which is investing $38 million into the company through an industrialization agreement in addition to a strong relationship with the Commonwealth of Pennsylvania
3. Starting next year, additional supply agreements in other therapeutic areas (outside of the SNY agreement) are anticipated
http://seekingalpha.com/article/161281-rodman-conference-recaps-exact-sciences-delcath-unilife?source=commenter
Add to My Watchlist
What is My Watchlist?
